European Commission logo
English English
CORDIS - EU research results

Microsensor for continuous arterial blood glucose monitoring


- Poor glucose control in critically ill patients leads to significant increases in costs, complication and mortality rates. Continuous monitoring of glucose will reduce costs of €2700 per patient and could save 58 000 lives in the EU every year.

- GlucoSet has developed a disposable glucose sensor for monitoring glucose in the ICU. The sensor measures glucose by measuring sub-nanometer length changes in an advanced material that responds to the glucose level. The product is designed for mass-manufacturing at its core. The innovative fiber optic sensor is protected by granted patents and has freedom to operate. The sensor will be sold as a single-use device lasting 96h with a gross margin of over 90% at high volume.

- The total addressable market (US and EU) is $1600 million per year. Willingness to pay has already been confirmed. The project has strong backing from key opinion leaders.

- Unlike the competition, the sensor couples to the indwelling arterial catheter, which enables unsurpassed reliability and ease of use.

- The SMEi phase 2 will take the project from working prototypes that have been tested in vivo, to a CE-marked device. We expect market entry in 2021 in the EU.

- The company has a very strong team that has extensive experience with medical devices, scaling up production and raising and working with venture capital.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 2 376 150,00
7037 Oslo

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Norge Trøndelag Trøndelag
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 6 368 407,50